A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
2019
Journal of Ovarian Research
Objective: Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated liposomal doxorubicin (PLD). Unfortunately, most patients do not benefit from treatment. Prediction of response is crucial to optimize PLD use and avoid unnecessary toxicities. We aimed at assessing the value of topoisomerase II alpha (TOP2A) expression as predictive marker of response to PLD-based therapy in patients with relapsed EOCs. Methods: We retrospectively analyzed Formalin Fixed Paraffin Embedded
doi:10.1186/s13048-019-0492-6
fatcat:3vyjvjhaf5c2fm2dettk7v37xe